Tag: bcma targeted therapies market research

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Rise In Market Size Of The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market During The Forecast Period?

The market size for b-cell maturation antigen (bcma) targeted therapies has experienced significant expansion in recent years. This market is projected to increase from $15.09 billion in 2025 to $18.75 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 24.3%. The growth witnessed in the historical period can be attributed to an improved understanding of bcma biology, the increasing prevalence of multiple myeloma, early successful clinical trials of bcma-targeted therapies, the expansion of hematology oncology centers, and rising investment in immuno-oncology research.

The b-cell maturation antigen (bcma) targeted therapies market is anticipated to experience substantial expansion in the coming years. This market is projected to reach $44.29 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 24.0%. This anticipated growth during the forecast period is driven by factors such as the increasing approvals of next-generation bcma therapies, a rising demand for off-the-shelf immunotherapies, the expansion of combination treatment strategies, a growing emphasis on durable remission outcomes, and the increasing application of AI-driven patient stratification. Key trends for this period encompass the increasing adoption of CAR-T cell therapies, the rising development of bispecific antibody platforms, the growing utilization of BCMA-targeted ADCs, the expansion of personalized immunotherapy regimens, and an enhanced focus on care for relapsed and refractory myeloma.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20718&type=smp

What Influential Factors Are Boosting The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Demand?

The increasing occurrence of multiple myeloma is projected to fuel the expansion of the b-cell maturation antigen (BCMA) targeted therapies market moving forward. Multiple myeloma is a cancer type primarily impacting plasma cells, which are vital components of the immune system responsible for antibody production. Several elements contribute to the rising prevalence of multiple myeloma, including an aging global populace, enhanced diagnostic capabilities, and disparities in healthcare availability. B-cell maturation antigen (BCMA) targeted therapies play a critical role in treating multiple myeloma by specifically targeting and eradicating malignant plasma cells that express BCMA, thereby presenting a hopeful method for more potent and focused treatment. For instance, in August 2024, data from the American Cancer Society, a US-based professional body, indicated that approximately 35,780 new multiple myeloma cases were diagnosed in the United States during 2024, comprising 19,520 cases in men and 16,260 in women. Furthermore, around 12,540 deaths are expected, with 7,020 among men and 5,520 among women. Consequently, the growing incidence of multiple myeloma is a significant catalyst for growth within the b-cell maturation antigen (BCMA) targeted therapies market.

How Is The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Structured Across Different Market Segments?

The b-cell maturation antigen (bcma) targeted therapies market covered in this report is segmented –

1) By Product Type: Antibody Drug Conjugates, Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, Bispecific Antibodies

2) By Indication Type: Multiple Myeloma, Plasma Cell Leukemia

3) By End User: Hospitals, Specialty Clinics

Subsegments:

1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates), Linker-Payload Technology-Based BCMA ADCs

2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous), Allogeneic BCMA CAR-T Cells

3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies, BCMA x CD28 Bispecific Antibodies

What Trends Are Affecting The Growth Of The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

Leading companies in the B-cell maturation antigen (BCMA) targeted therapies market are concentrating on developing innovative treatments, such as CAR-T cell therapy, to improve the effectiveness and precision of targeting cancer cells. This CAR-T cell therapy represents a type of immunotherapy that involves modifying a patient’s T cells to express chimeric antigen receptors (CARs) for the purpose of targeting and eliminating cancer cells. For example, in April 2024, Johnson & Johnson, a US-based pharmaceutical industry company, obtained U.S. Food and Drug Administration (FDA) approval for CARVYKTI. CARVYKTI (ciltacabtagene autoleucel) is a BCMA-targeted, genetically modified autologous T-cell immunotherapy designed for treating adult patients with relapsed or refractory multiple myeloma who have received a minimum of one prior line of therapy and are resistant to lenalidomide.

Who Are The Firms Contributing To The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Ecosystem?

Major companies operating in the b-cell maturation antigen (bcma) targeted therapies market are Bristol Myers Squibb Company, Novartis, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, BeiGene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Allogene Therapeutics, Affimed, Bluebird Bio Inc, Roche, Ichnos Sciences

Access The Complete B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report:

https://www.thebusinessresearchcompany.com/report/b-cell-maturation-antigen-bcma-targeted-therapies-global-market-report

Which Region Contributes The Most To The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2025. The regions covered in the b-cell maturation antigen (bcma) targeted therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=20718&type=smp

Browse Through More Reports Similar to the Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market 2026, By The Business Research Company

Malignant Melanoma Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/malignant-melanoma-treatment-global-market-report

Oral Cancer Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-cancer-treatment-global-market-report

Neuroendocrine Tumor Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuroendocrine-tumor-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Compression Sleeves Market Projected To Reach By 2030?

The compression sleeves market has demonstrated significant expansion in recent years. Projections show its value increasing from $1.38 billion in 2025 to $1.47 billion by 2026, reflecting a compound annual growth rate (CAGR) of 6.7%. This historic period’s growth is primarily due to higher rates of sports participation, a rise in musculoskeletal injuries, the broadening of rehabilitation and physiotherapy services, greater consumer health awareness, and the increased application of compression for athletic recovery.

The compression sleeves market size is expected to experience robust growth in the upcoming years. It is anticipated to expand to $1.83 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.6%. This expansion during the forecast period can be attributed to factors such as increasing demand for apparel that enhances performance, a growing adoption of compression wear for preventive care, the broadening of online retail channels, a heightened focus on wearable health support products, and increasing innovation in smart compression garments. Significant trends foreseen in this period include a rising embrace of sports and medical compression sleeves, an increased preference for graduated compression designs, the growing integration of breathable and moisture-wicking fabrics, the further expansion of e-commerce distribution channels, and an enhanced emphasis on ergonomic fit and aesthetics.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/compression-sleeves-global-market-report

Which Key Factors Are Driving The Compression Sleeves Market Growth?

The expansion of the compression sleeves market is propelled by the growing occurrence of deep vein thrombosis. Deep vein thrombosis (DVT) is a medical condition characterized by the formation of a blood clot in one or more deep veins, most frequently in the legs. The increase in DVT prevalence stems from various factors, including lifestyle choices, existing medical conditions, genetic predispositions, and environmental influences. Compression sleeves play a crucial role in managing deep vein thrombosis by enhancing blood circulation, alleviating leg pain and swelling, and mitigating the danger of clot formation. As an illustration, a report issued in October 2024 by the National Center for Biotechnology Information (NCBI), a division of the US-based National Library of Medicine (NLM), showed that lower extremity DVTs represented 88.5% of cases with an admission rate of 32.1%, while upper extremity DVTs accounted for 11.7% of cases with a 37.0% admission rate. Hence, the rising prevalence of deep vein thrombosis is a key driver for the compression sleeves market.

What Are The Key Segment Divisions In The Compression Sleeves Market Segment Structure?

The compression sleeves market covered in this report is segmented –

1) By Product: Arm Compression Sleeves, Bandages, Leg Compression Sleeves, Other Products

2) By Technique: Static, Dynamic

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Sales, Hypermarkets

4) By Application: Varicose Veins, Wound Care, Burns, Oncology, Other Applications

Subsegments:

1) By Arm Compression Sleeves: Full-Length Arm Sleeves, Elbow Sleeves, Compression Gloves, Forearm Sleeves, Compression Sleeves With Padding

2) By Bandages: Elastic Bandages, Compression Wraps, Kinesiology Tape, Self-Adhesive Bandages, Sports Bandages

3) By Leg Compression Sleeves: Full-Length Leg Sleeves, Calf Sleeves, Knee Sleeves, Compression Socks, Thigh Sleeves

4) By Other Products: Compression Shorts, Compression Shirts, Compression Wraps For Injuries, Compression Hosiery, Compression Vests

Which Trends Are Guiding The Direction Of The Compression Sleeves Market?

Major companies in the compression sleeves market are concentrating on creating innovative solutions, including portable pneumatic (air-powered) calf compression sleeves. These advanced designs incorporate on-device pumps and rechargeable batteries to deliver graduated, programmable compression for enhanced recovery and circulation support. This innovation addresses the increasing demand from athletes, travellers, and medical-rehabilitation users for quicker, mobile recovery and effective DVT swelling management. Unlike conventional elastic or knit compression sleeves, pneumatic (air) compression sleeves utilize inflatable chambers that rhythmically expand and contract, generating a flushing action that moves blood and lymph upwards. As an illustration, in June 2023, Recovery Systems, a Singapore-based recovery-devices company, launched the ATOM calf air compression sleeve. This portable, battery-powered pneumatic sleeve is engineered for warm-up, recovery, and massage. The ATOM features Velcro-fitted adjustable wraps with internal air chambers and a Type-C rechargeable battery, providing three treatments and four pressure levels. Its one-size-fits-most Velcro adjustable cuff design allows for use on either calves or arms, highlighting its portability and travel-friendliness.

Which Organizations Are Engaged In The Compression Sleeves Market?

Major companies operating in the compression sleeves market are Medi USA, Zensah, 2XU Pty. Ltd, Mueller Sports Medicine, Vive Health, Sigvaris Group, CEP Compression, Rehband, Copper Fit, Mava Sports, Zamst, Vitalsox, Under Armour, Tommie Copper, Therafirm, SKINS Compression, Shock Doctor Inc, Run Forever Sports, Pro-Tec Athletics, OS1st, Orthosleeve, Mojo Compression, McDavid, EvoShield, CW-X

Get The Full Compression Sleeves Market Report:

https://www.thebusinessresearchcompany.com/report/compression-sleeves-global-market-report

Which Region Holds The Highest Market Share In The Compression Sleeves Market?

North America was the largest region in the compression sleeves market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the compression sleeves market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Compression Sleeves Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/compression-sleeves-global-market-report

Browse Through More Reports Similar to the Global Compression Sleeves Market 2026, By The Business Research Company

Compression Garments And Stockings Market Report 2026

https://www.thebusinessresearchcompany.com/report/compression-garments-and-stockings-global-market-report

Compression Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/compression-therapy-global-market-report

Compression Stockings Market Report 2026

https://www.thebusinessresearchcompany.com/report/compression-stockings-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Progress Between 2026 And 2030?

The b-cell maturation antigen (bcma) targeted therapies market size has experienced substantial expansion in recent years. This market is expected to increase from $15.09 billion in 2025 to $18.75 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 24.3%. The historical growth of this market can be linked to an enhanced comprehension of BCMA biology, the growing prevalence of multiple myeloma, initial successful clinical outcomes for BCMA-targeted therapies, the proliferation of hematology oncology centers, and increased investment in immuno-oncology research.

The b-cell maturation antigen (bcma) targeted therapies market size is anticipated to undergo significant expansion over the coming years. It is projected to achieve a valuation of $44.29 billion by 2030, demonstrating a robust compound annual growth rate (CAGR) of 24.0%. This projected growth is driven by several factors, including the increasing approval of next-generation BCMA therapies, a growing demand for readily available immunotherapies, the broadening of combination treatment approaches, a heightened emphasis on achieving long-lasting remission, and the expanding application of AI-powered patient stratification. Key developments expected during this period include the wider adoption of CAR-T cell therapies, the advancement in developing bispecific antibody platforms, the increased utilization of BCMA-targeted ADCs, the broadening of personalized immunotherapy regimens, and an intensified focus on managing relapsed and refractory myeloma.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/b-cell-maturation-antigen-bcma-targeted-therapies-global-market-report

Which Strong Drivers Are Impacting The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth?

The increasing occurrence of multiple myeloma is projected to drive expansion within the b-cell maturation antigen (BCMA) targeted therapies market in the future. Multiple myeloma is defined as a form of cancer predominantly impacting plasma cells, vital immune system constituents tasked with generating antibodies. This growing prevalence of multiple myeloma stems from various causes, such as an aging worldwide populace, advancements in diagnostic methods, and disparities in healthcare accessibility. B-cell maturation antigen (BCMA) targeted therapies play a critical role in combating multiple myeloma by specifically identifying and destroying cancerous plasma cells that display BCMA, thereby presenting a promising strategy for more potent and precise treatment. For example, data from August 2024, provided by the American Cancer Society, a US-based professional organization, indicated that in 2024, roughly 35,780 new multiple myeloma cases were identified in the United States, comprising 19,520 cases among men and 16,260 among women. Furthermore, an estimated 12,540 fatalities are expected, consisting of 7,020 male deaths and 5,520 female deaths. Consequently, the increasing incidence of multiple myeloma is stimulating growth in the b-cell maturation antigen (BCMA) targeted therapies market.

What Are The Key Segment Divisions In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Segment Structure?

The b-cell maturation antigen (bcma) targeted therapies market covered in this report is segmented –

1) By Product Type: Antibody Drug Conjugates, Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, Bispecific Antibodies

2) By Indication Type: Multiple Myeloma, Plasma Cell Leukemia

3) By End User: Hospitals, Specialty Clinics

Subsegments:

1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates), Linker-Payload Technology-Based BCMA ADCs

2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous), Allogeneic BCMA CAR-T Cells

3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies, BCMA x CD28 Bispecific Antibodies

Which Trends Are Contributing To Changes In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

Leading companies within the B-cell maturation antigen (BCMA) targeted therapies market are dedicated to developing advanced treatments, such as CAR-T cell therapy, to boost the effectiveness and accuracy of targeting cancer cells. CAR-T cell therapy operates as an immunotherapy, where a patient’s T cells are genetically altered to express chimeric antigen receptors (CARs), enabling them to specifically identify and eradicate cancer cells. For example, in April 2024, Johnson & Johnson, a US-based pharmaceutical industry company, obtained U.S. Food and Drug Administration (FDA) approval for CARVYKTI. CARVYKTI (ciltacabtagene autoleucel) is a BCMA-targeted, genetically modified autologous T-cell immunotherapy intended for the treatment of adult patients diagnosed with relapsed or refractory multiple myeloma who have undergone at least one prior line of therapy and are refractory to lenalidomide.

Which Organizations Are Engaged In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

Major companies operating in the b-cell maturation antigen (bcma) targeted therapies market are Bristol Myers Squibb Company, Novartis, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, BeiGene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Allogene Therapeutics, Affimed, Bluebird Bio Inc, Roche, Ichnos Sciences

Get The Full B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report:

https://www.thebusinessresearchcompany.com/report/b-cell-maturation-antigen-bcma-targeted-therapies-global-market-report

Where Is The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Most Concentrated Geographically?

North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2025. The regions covered in the b-cell maturation antigen (bcma) targeted therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/b-cell-maturation-antigen-bcma-targeted-therapies-global-market-report

Browse Through More Reports Similar to the Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market 2026, By The Business Research Company

Preventive Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Next Generation Antibody Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Diffuse Large B Cell Lymphoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/diffuse-large-b-cell-lymphoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Progress Between 2026 And 2030?

The b-cell maturation antigen (bcma) targeted therapies market size has experienced substantial expansion in recent years. This market is expected to increase from $15.09 billion in 2025 to $18.75 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 24.3%. The historical growth of this market can be linked to an enhanced comprehension of BCMA biology, the growing prevalence of multiple myeloma, initial successful clinical outcomes for BCMA-targeted therapies, the proliferation of hematology oncology centers, and increased investment in immuno-oncology research.

The b-cell maturation antigen (bcma) targeted therapies market size is anticipated to undergo significant expansion over the coming years. It is projected to achieve a valuation of $44.29 billion by 2030, demonstrating a robust compound annual growth rate (CAGR) of 24.0%. This projected growth is driven by several factors, including the increasing approval of next-generation BCMA therapies, a growing demand for readily available immunotherapies, the broadening of combination treatment approaches, a heightened emphasis on achieving long-lasting remission, and the expanding application of AI-powered patient stratification. Key developments expected during this period include the wider adoption of CAR-T cell therapies, the advancement in developing bispecific antibody platforms, the increased utilization of BCMA-targeted ADCs, the broadening of personalized immunotherapy regimens, and an intensified focus on managing relapsed and refractory myeloma.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/b-cell-maturation-antigen-bcma-targeted-therapies-global-market-report

Which Strong Drivers Are Impacting The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth?

The increasing occurrence of multiple myeloma is projected to drive expansion within the b-cell maturation antigen (BCMA) targeted therapies market in the future. Multiple myeloma is defined as a form of cancer predominantly impacting plasma cells, vital immune system constituents tasked with generating antibodies. This growing prevalence of multiple myeloma stems from various causes, such as an aging worldwide populace, advancements in diagnostic methods, and disparities in healthcare accessibility. B-cell maturation antigen (BCMA) targeted therapies play a critical role in combating multiple myeloma by specifically identifying and destroying cancerous plasma cells that display BCMA, thereby presenting a promising strategy for more potent and precise treatment. For example, data from August 2024, provided by the American Cancer Society, a US-based professional organization, indicated that in 2024, roughly 35,780 new multiple myeloma cases were identified in the United States, comprising 19,520 cases among men and 16,260 among women. Furthermore, an estimated 12,540 fatalities are expected, consisting of 7,020 male deaths and 5,520 female deaths. Consequently, the increasing incidence of multiple myeloma is stimulating growth in the b-cell maturation antigen (BCMA) targeted therapies market.

What Are The Key Segment Divisions In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Segment Structure?

The b-cell maturation antigen (bcma) targeted therapies market covered in this report is segmented –

1) By Product Type: Antibody Drug Conjugates, Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, Bispecific Antibodies

2) By Indication Type: Multiple Myeloma, Plasma Cell Leukemia

3) By End User: Hospitals, Specialty Clinics

Subsegments:

1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates), Linker-Payload Technology-Based BCMA ADCs

2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous), Allogeneic BCMA CAR-T Cells

3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies, BCMA x CD28 Bispecific Antibodies

Which Trends Are Contributing To Changes In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

Leading companies within the B-cell maturation antigen (BCMA) targeted therapies market are dedicated to developing advanced treatments, such as CAR-T cell therapy, to boost the effectiveness and accuracy of targeting cancer cells. CAR-T cell therapy operates as an immunotherapy, where a patient’s T cells are genetically altered to express chimeric antigen receptors (CARs), enabling them to specifically identify and eradicate cancer cells. For example, in April 2024, Johnson & Johnson, a US-based pharmaceutical industry company, obtained U.S. Food and Drug Administration (FDA) approval for CARVYKTI. CARVYKTI (ciltacabtagene autoleucel) is a BCMA-targeted, genetically modified autologous T-cell immunotherapy intended for the treatment of adult patients diagnosed with relapsed or refractory multiple myeloma who have undergone at least one prior line of therapy and are refractory to lenalidomide.

Which Organizations Are Engaged In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

Major companies operating in the b-cell maturation antigen (bcma) targeted therapies market are Bristol Myers Squibb Company, Novartis, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, BeiGene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Allogene Therapeutics, Affimed, Bluebird Bio Inc, Roche, Ichnos Sciences

Get The Full B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report:

https://www.thebusinessresearchcompany.com/report/b-cell-maturation-antigen-bcma-targeted-therapies-global-market-report

Where Is The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Most Concentrated Geographically?

North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2025. The regions covered in the b-cell maturation antigen (bcma) targeted therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/b-cell-maturation-antigen-bcma-targeted-therapies-global-market-report

Browse Through More Reports Similar to the Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market 2026, By The Business Research Company

Preventive Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Next Generation Antibody Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Diffuse Large B Cell Lymphoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/diffuse-large-b-cell-lymphoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market At The End Of The 2026–2030 Forecast Period?

The b-cell maturation antigen (bcma) targeted therapies market size has seen significant expansion over recent years. It is anticipated to increase from $15.09 billion in 2025 to $18.75 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 24.3%. The historical growth of this market can be ascribed to an improved understanding of bcma biology, the increasing prevalence of multiple myeloma, the early clinical success observed with bcma-targeted therapies, the expansion of hematology oncology centers, and rising investment in immuno-oncology research.

The b-cell maturation antigen (bcma) targeted therapies market is projected for significant expansion in the coming years, reaching a size of $44.29 billion by 2030, driven by a compound annual growth rate (CAGR) of 24.0%. This projected growth during the forecast period is fueled by several factors, including the rising number of approvals for advanced bcma therapies, an increasing need for ready-to-use immunotherapies, the broadening of combination treatment approaches, a heightened emphasis on achieving lasting remission, and the growing application of AI in patient stratification. Key trends anticipated for this period involve the greater uptake of CAR-T cell therapies, the increasing creation of bispecific antibody platforms, the expanded application of BCMA-targeted ADCs, the development of individualized immunotherapy regimens, and a stronger focus on managing relapsed and refractory myeloma.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20718&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

The increasing occurrence of multiple myeloma is anticipated to drive expansion in the b-cell maturation antigen (BCMA) targeted therapies market. Multiple myeloma, a form of cancer, predominantly impacts plasma cells, which are vital immune system components involved in antibody production. Several factors contribute to the escalating incidence of multiple myeloma, such as the worldwide aging population, advancements in diagnostic methods, and differences in healthcare accessibility. BCMA targeted therapies play a vital role in managing multiple myeloma by specifically identifying and eradicating cancerous plasma cells displaying BCMA, thus presenting a promising strategy for more precise and impactful treatment. For example, in August 2024, data from the American Cancer Society, a US-based professional organization, indicated that in 2024, roughly 35,780 new multiple myeloma cases were identified in the United States, comprising 19,520 cases among men and 16,260 among women. Furthermore, around 12,540 fatalities are projected, with 7,020 among men and 5,520 among women. Consequently, the increased prevalence of multiple myeloma is fueling the expansion of the b-cell maturation antigen (BCMA) targeted therapies market.

What Segment Types Make Up The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

The b-cell maturation antigen (bcma) targeted therapies market covered in this report is segmented –

1) By Product Type: Antibody Drug Conjugates, Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, Bispecific Antibodies

2) By Indication Type: Multiple Myeloma, Plasma Cell Leukemia

3) By End User: Hospitals, Specialty Clinics

Subsegments:

1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates), Linker-Payload Technology-Based BCMA ADCs

2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous), Allogeneic BCMA CAR-T Cells

3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies, BCMA x CD28 Bispecific Antibodies

What Key Trends Are Influencing The Development Of The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

Leading firms within the B-cell maturation antigen (BCMA) targeted therapies market are concentrating on creating novel therapies, including CAR-T cell therapy, to improve the effectiveness and accuracy of targeting malignant cells. This immunotherapy, known as CAR-T cell therapy, works by genetically altering a patient’s T cells to display chimeric antigen receptors (CARs), enabling them to identify and eliminate cancer cells. As an example, in April 2024, the US pharmaceutical company Johnson & Johnson secured approval from the U.S. Food and Drug Administration (FDA) for its product CARVYKTI. CARVYKTI (ciltacabtagene autoleucel) represents a BCMA-targeted, autologous T-cell immunotherapy, genetically modified to treat adult patients afflicted with relapsed or refractory multiple myeloma, specifically those who have undergone at least one previous therapy and have shown resistance to lenalidomide.

Who Are The Key Players Driving Competition In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

Major companies operating in the b-cell maturation antigen (bcma) targeted therapies market are Bristol Myers Squibb Company, Novartis, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, BeiGene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Allogene Therapeutics, Affimed, Bluebird Bio Inc, Roche, Ichnos Sciences

Read the full b-cell maturation antigen (bcma) targeted therapies market report here:

https://www.thebusinessresearchcompany.com/report/b-cell-maturation-antigen-bcma-targeted-therapies-global-market-report

Which Regions Are Projected To Dominate The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market In The Coming Years?

North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2025. The regions covered in the b-cell maturation antigen (bcma) targeted therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20718&type=smp

Browse Through More Reports Similar to the Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market 2026, By The Business Research Company

Malignant Melanoma Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/malignant-melanoma-treatment-global-market-report

Oral Cancer Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/oral-cancer-treatment-global-market-report

Neuroendocrine Tumor Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/neuroendocrine-tumor-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model